Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protalix Biotherapeutics (NY: PLX ) 1.090 UNCHANGED Official Closing Price Updated: 6:30 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Protalix Biotherapeutics < Previous 1 2 3 Next > Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire Life Sciences Virtual Investor Forum Agenda Announced for September 19th September 16, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024 August 14, 2024 PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Friday's Pre-Market Session May 17, 2024 Via Benzinga Earnings Preview: Protalix BioTherapeutics March 13, 2024 Via Benzinga Earnings Scheduled For November 6, 2023 November 06, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. Via Benzinga Earnings Preview For Protalix BioTherapeutics November 03, 2023 Via Benzinga PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024 May 10, 2024 PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Friday's Pre-Market Session May 10, 2024 Via Benzinga Earnings Scheduled For March 14, 2024 March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. Via Benzinga Pullix Gains Momentum As Gamestop Exits NFT Space January 14, 2024 Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for... Via Talk Markets Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying October 23, 2023 The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session August 07, 2023 Via Benzinga Preview: Protalix BioTherapeutics's Earnings August 04, 2023 Via Benzinga Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics May 10, 2023 The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult Via Benzinga Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil May 04, 2023 Via Benzinga Earnings Preview For Protalix BioTherapeutics February 24, 2023 Via Benzinga Looking Into Protalix BioTherapeutics's Return On Capital Employed December 23, 2022 Via Benzinga Protalix BioTherapeutics Well Placed to Advance in 2023 December 12, 2022 We see a number of reasons to be positive about PLX shares in 2023 and investors should take note. Via Talk Markets Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 10, 2023 It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! Via InvestorPlace Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket February 27, 2023 Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses. Via Benzinga $12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying January 06, 2023 The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Earnings Scheduled For February 27, 2023 February 27, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. Via Benzinga Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment November 30, 2022 By David Willey, Benzinga Via News Direct Exposures Product Safety Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment November 30, 2022 Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License... Via TheNewswire.com Exposures Product Safety Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment November 29, 2022 Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, Via Benzinga Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions September 21, 2022 As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... Via TheNewswire.com Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions September 21, 2022 By Mark Gilman, Benzinga Via News Direct Earnings Scheduled For November 14, 2022 November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. Via Benzinga Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions September 20, 2022 As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.